ライフサイエンスコーパス: WHO

1 WHO and countries are setting ambitious goals for reduci

2 WHO and United Nations Children's Fund data from 2013-20

3 WHO criteria were used to define immunologic treatment f

4 WHO estimated that nearly 1 million people become infect

5 WHO estimates exposure to air pollution from cooking wit

6 WHO guidelines for these regions define failure of ART w

7 WHO has defined a Roadmap to reach 2020 targets, which w

8 WHO has proposed a pragmatic screening approach for mana

9 WHO is committed to supporting country, global, regional

10 WHO must also evolve its governance to become far more w

11 WHO now recommends the use of Xpert Ultra as the initial

12 WHO reported that more than 1 billion people in 88 count

13 WHO's End TB Strategy recognises and aims to eliminate t

14 /mul versus 214 cells/mul (p < 0.001), 61.1% WHO stage 3/4 disease versus 42.8% (p < 0.001), and pre-

15 ding 1 patient with 2 lesions], WHO III: 17, WHO IV: 13, without biopsy low-grade: 1, high-grade: 1)

16 Therefore, in 1981, WHO recommended that all registered patients with lepros

17 ts to confirm konzo diagnosis using the 1996 WHO criteria at 2 years and 4 years.

18 The 1st WHO International Standard for BKV (primary standard) wa

19 can Society of Anesthesiologists score </=2, WHO/ECOG score </=1, age </=65 years, body mass index 19

20 emia or polycythaemia vera according to 2001 WHO criteria were eligible to enrol in our study.

21 ght-for-length z scores (WLZs), but the 2006 WHO standards exclude infants shorter than 45 cm.

22 mphomas were reviewed, according to the 2008 WHO classification, in real time by experts through the

23 Health Organization (WHO), but in early 2009 WHO's Strategic Advisory Group of Experts on Immunizatio

24 In 2011, WHO member states signed up to the 25 x 25 initiative, a

25 ntiretroviral therapy (ART), as per the 2015 WHO recommendations, might reduce population HIV inciden

26 The new 2016 WHO brain tumor classification defines different diffuse

27 The guideline is based on the 2016 WHO classification of tumours of the central nervous sys

28 -life" study indicate that adherence to 2016 WHO criteria allows for identification of 2 distinct cat

29 In February, 2016, WHO released a report for the development of national ac

30 In 2016, WHO adopted a strategy for the elimination of viral hepa

31 In 2016, WHO declared the recent cluster of microcephaly cases an

32 In May, 2016, WHO endorsed a 9 month regimen for multidrug-resistant t

33 Collectively, the database covered all 6 WHO geographic regions and contained approximately 30,00

34 Results Treatment response occurred in 5.9% (WHO criteria), 2.0% (RECIST), 25.5% (mRECIST), and 23.5%

35 within 12 months before randomisation, and a WHO performance status of 0-2.

36 probe binding regions, while evaluation of a WHO international reference panel for HEV genotypes (cod

37 ss' in the left side of her vision, due to a WHO grade III anaplastic haemangiopericytoma compressing

38 Other inclusion criteria were a WHO performance status of 0-2, adequate organ function a

39 evels in ICS households still remained above WHO guidelines.

40 funding for malaria is inadequate to achieve WHO global targets in burden reduction by 2030.

41 counts and hemoglobin levels, more advanced WHO stage, and higher HIV RNA levels.

42 n high-grade glioma (AUC, 0.854) and for all WHO grades (AUC, 0.899) among all biomarkers.

43 Although WHO recommends viral load (VL) monitoring for those on a

44 ,), coronary artery disease ( P < .001), and WHO/International Society of Hypertension score ( P = .0

45 on the WHO definition of unsafe abortion and WHO guidelines on safe abortion to categorise abortions

46 The DNA methylation-based and WHO classification schema were compared using the Brier

47 tment, adjusting for age, baseline CD4+, and WHO stage.

48 ity and specificity of point-of-care CRP and WHO symptom-based screening in reference to culture resu

49 andard, sensitivity of point-of-care CRP and WHO symptom-based screening were similar (94% [79 of 84]

50 bodies, with extensive human safety data and WHO-standardized international manufacturing capability

51 call for governments, academia, funders, and WHO to strengthen programmes and enhance research in aed

52 as the UN Sustainable Development Goals and WHO's climate and health country profiles.

53 or geographical subregion, income level, and WHO FCTC party status, the per-measure decrease in preva

54 arched CENTRAL, CINAHL, Embase, MEDLINE, and WHO IRIS databases for publications between Jan 1, 2000,

55 TT improved nontechnical skills and WHO compliance (P < 0.001), but not technical performanc

56 ghly reproducible for 3 CMV virus stocks and WHO IS (P > .80), tested by three sets of paired q-PCR.

57 del to data from drug resistance surveys and WHO tuberculosis reports to forecast estimates of incide

58 s of tumors of the same morphologic type and WHO grade to be distinguished and are, therefore, of gre

59 ination and collaboration between UNICEF and WHO and with partners, ensured success of this major, hi

60 uses remained related to earlier viruses and WHO-recommended prepandemic vaccine strains representing

61 ion deaths in 2015 alone based on the annual WHO report, due to inadequate health service resources i

62 n or multiantigen set performance approached WHO TPP criteria for clinical utility among HIV-uninfect

63 The largest area (WHO), longest diameter (RECIST), longest enhancing diame

64 ress rapidly and are therefore classified as WHO grade III or IV high-grade gliomas (HGGs).

65 Patients identified as WHO functional class II-IV with a pulmonary vascular res

66 original 2001 WHA resolution and associated WHO guidelines on preventive chemotherapy.

67 results, 22 of 98 (22.4%) had no symptoms at WHO 4-symptom screening.

68 Against this background, WHO made it a high priority to provide the present fetal

69 r in facilities that used the coaching-based WHO Safe Childbirth Checklist program than in those that

70 whom first-line ART had failed (assessed by WHO criteria with virological confirmation) were randoml

71 ogistics, and management across countries by WHO in collaboration with the United Nations Children's

72 Overweight or obesity was defined by WHO cutoffs.

73 ons in accordance with indicators defined by WHO, UNAIDS, and the UN Office on Drugs and Crime.

74 alling within the result ranges generated by WHO collaborative study participants for all panel membe

75 priority epidemiological gaps highlighted by WHO to inform potential maternal vaccination.

76 rable global health burden, as recognised by WHO's Battle against Respiratory Viruses initiative.

77 smodium falciparum malaria is recommended by WHO in some settings.

78 n aged <3 years are currently recommended by WHO, but the implementation of this recommendation is su

79 population coverage threshold recommended by WHO; this represents between 43% and 52% of the populati

80 stant tuberculosis has been long regarded by WHO as a global priority for investment in new drugs.

81 patients with metastatic colorectal cancer (WHO performance status 0 or 1) with liver metastases not

82 After controlling for baseline CD4+, WHO stage, and age, this effect remained significant (ad

83 WHO Framework Convention on Tobacco Control (WHO FCTC) has mobilised efforts among 180 parties to com

84 Current WHO guidelines recommend initiating ART regardless of CD

85 INTERPRETATION: Current WHO guidelines appear to manage dysentery effectively, b

86 d to validate their inclusion in the current WHO-defined group of eosinophilia-associated TK fusion-d

87 and we generated separate estimates for each WHO region, which were then summed to obtain global esti

88 e compiled data from a range of sources (eg, WHO reports and health-service-provider registeries) rep

89 empower the next Director-General to enable WHO to be a bulwark for health and human rights, serving

90 meric mRNAs in one infratentorial ependymoma WHO III, arguing that this fusion occurs in a small prop

91 ents had at least one severe bleeding event (WHO bleeding score >/=2).

92 5) improved all performance measures except WHO time-out attempts, whereas single approaches (1 & 2

93 +/-2.15mgg(-1)) which were comparable to FAO/WHO requirements.

94 Finally, WHO regional and global mean prevalence of FASD weighted

95 logy for burden estimation and present first WHO global and regional estimates of the annual number o

96 ussed and implemented.The SEAR was the first WHO Region globally to complete the switch and declare t

97 is to be included into the ICD-11 framework, WHO has recognized their importance not only to clinicia

98 UNAIDS) from 1988 to 2013 and from data from WHO on tuberculosis from 1980 to to 2013 to fit a dynami

99 conditional programmatic recommendation from WHO.

100 tic glioma (WHO grade III) and glioblastoma (WHO grade IV) showed decreased OEF when compared with no

101 < .001, n = 20), whereas anaplastic glioma (WHO grade III) and glioblastoma (WHO grade IV) showed de

102 Results Low-grade (WHO grade II) glioma showed areas with increased OEF (+1

103 ibility criteria with the addition of having WHO-defined radiological pneumonia.

104 WHO] grade II) from high-grade glioma (HGG) (WHO grade III or IV).

105 South Africa had moved swiftly to implement WHO guidelines (2004-2013) and had achieved high levels

106 ereas single approaches (1 & 2 & 3) improved WHO compliance less (P < 0.001) and failed to improve te

107 chnical performance (P < 0.001) but improved WHO compliance less.

108 n to test the relationship between change in WHO drinking risk levels between Waves 1 and 2, and alco

109 ng meaningful civil society participation in WHO's governance and standing up for the right to health

110 ion and licensure pathways, participation in WHO-convened joint reviews of licensing dossiers, as wel

111 Reduction in WHO drinking risk level predicted significantly lower od

112 s in clinical trials, including reduction in WHO drinking risk levels-very high, high, moderate, and

113 Our results support the use of reductions in WHO drinking risk levels as an efficacy outcome in clini

114 Eligibility criteria included WHO performance status 0 or 1, adequate respiratory, car

115 1 751 479 (54% women) from seven high-income WHO member countries.

116 INTERPRETATION: WHO's pragmatic, symptom-based algorithm was an effectiv

117 -level viraemia need to be incorporated into WHO guidelines to meet UNAIDS-defined targets aimed at h

118 INTERPRETATION: Implementation of key WHO FCTC demand-reduction measures is significantly asso

119 II: 10 [including 1 patient with 2 lesions], WHO III: 17, WHO IV: 13, without biopsy low-grade: 1, hi

120 rld Health Organization's recommended level (WHO-MCL = 1.5 mg F(-)/L).

121 data and evidence from published literature, WHO meeting reports, cancer control mission reports, and

122 mentations of key demand-reduction measures (WHO FCTC articles 6, 8, 11, 13, and 14) between 2007 and

123 These findings have implications for meeting WHO targets, with evidence of some countries not followi

124 A modified WHO decision-tree designed to detect high-risk asymptoma

125 Objective response rate by modified WHO criteria was 42%, and median duration of response wa

126 6 months (Botswana guidelines) or 12 months (WHO guidelines).

127 8.5% female; median CD4 cell count, 278/muL; WHO HIV stage I, 66.8%), 98 (10.1%) tested positive with

128 ce of pretreatment NNRTI resistance was near WHO's 10% threshold for changing first-line ART in south

129 Three candidates to be the next WHO Director-General remain: Tedros Adhanom Ghebreyesus,

130 ence (cm), whole body fat (kg), and obesity (WHO criteria of BMI >/=30 kg/m(2)) on residential densit

131 rategy endorsed by the health authorities of WHO Member States in 2014 to achieve a world free of tub

132 s been hoped that the recent availability of WHO quantitative standards would improve interlaboratory

133 The 22 countries of WHO's Eastern Mediterranean Region are experiencing an i

134 national levels to inform the development of WHO guidelines on the core components of national IPC pr

135 nch that mentioned at least one dimension of WHO's palliative care public health strategy (implementa

136 hrough an analysis of the financial flows of WHO, the World Bank, the Global Fund to Fight HIV/AIDS,

137 L respectively according to the guideline of WHO.

138 sis to investigate whether implementation of WHO's recommended tobacco control policies (MPOWER) was

139 rbor stage III or IV) follicular lymphoma of WHO histological grades 1, 2, or 3a were randomly assign

140 imated to be missed annually, and in view of WHO's end TB strategy endorsed by the health authorities

141 e derived using a top-down approach based on WHO general health expenditure figures and prevalence da

142 Distributions of HAZ (based on WHO growth standards) were analysed in 3-month age inter

143 HAP plus EUC also had a marginal effect on WHO Disability Assessment Schedule score at 12 months (a

144 We searched PubMed, African Journals Online, WHO Global Health Library, and Web of Science for articl

145 appeared to be independent of CD4+ count or WHO stage.

146 ombined approach: World Health Organization (WHO) 4-symptom screening (fever, cough, night sweats, an

147 countries of the World Health Organization (WHO) African Region switched from the use of tOPV to bOP

148 ulatory agencies, World Health Organization (WHO) and United Nations Children's Fund (UNICEF) regiona

149 recognized by the World Health Organization (WHO) category, "Myeloid/lymphoid neoplasms with eosinoph

150 l performance and World Health Organization (WHO) checklist compliance, measured for 3 months before

151 6 revision of the World Health Organization (WHO) classification for lymphoma has included a new cate

152 6 revision of the World Health Organization (WHO) classification of myeloproliferative neoplasms defi

153 nct entity in the World Health Organization (WHO) classification system, is readily recognized as a p

154 The World Health Organization (WHO) coordinates global laboratory surveillance of vacci

155 We used the 1999 World Health Organization (WHO) criteria to define GDM: >/=7.0 mmol/L for fasting g

156 determined using World Health Organization (WHO) criteria.

157 sification of the World Health Organization (WHO) divides the disease into cutaneous mastocytosis, sy

158 ped and graded as World Health Organization (WHO) grades I-IV according to increasing degrees of mali

159 nd 2014 following World Health Organization (WHO) guidance.

160 nsistent with the World Health Organization (WHO) Guidelines for Accurate and Transparent Health Esti

161 ical practice-the World Health Organization (WHO) has described this task as one of the greatest chal

162 69) and the first World Health Organization (WHO) international standard (IS) for CMV DNA.

163 ed with the first World Health Organization (WHO) international standard for HEV RNA (code 6329/10),

164 The World Health Organization (WHO) methodology for the interpretation of pediatric CXR

165 ptance for use of World Health Organization (WHO) prequalified vaccines, registration and licensure p

166 Code System is a World Health Organization (WHO) proposed classification that assigns multi-level co

167 The World Health Organization (WHO) recommends integrated vector management (IVM) strat

168 The World Health Organization (WHO) recommends that people travelling to or living in a

169 he country (NCC), World Health Organization (WHO) region (RCC), or globally (GCC).

170 on by country, by World Health Organization (WHO) region, and globally.

171 The World Health Organization (WHO) Safe Childbirth Checklist, a quality-improvement to

172 imit according to World Health Organization (WHO) standard.

173 The World Health Organization (WHO) stated that globally, dental caries is the most imp

174 We used World Health Organization (WHO) target product profile (TPP) criteria for a detecti

175 The World Health Organization (WHO) Western Pacific Region (WPR) has maintained its pol

176 this issue in the World Health Organization (WHO) World Mental Health (WMH) Surveys with 34 676 respo

177 According to the World Health Organization (WHO), almost 2 billion people each year are infected wor

178 ecommended by the World Health Organization (WHO), but in early 2009 WHO's Strategic Advisory Group o

179 ty, including the World Health Organization (WHO), has committed to ending the AIDS epidemic and to e

180 vival better than World Health Organization (WHO), Response Evaluation Criteria in Solid Tumors (RECI

181 nership among the World Health Organization (WHO), Rotary International, the Centers for Disease Cont

182 progress reports, World Health Organization (WHO), UNAIDS reports, national surveillance and program

183 sus group and the World Health Organization (WHO).

184 tions such as the World Health Organization (WHO).

185 ade glioma (LGG) (World Health Organization [WHO] grade II) from high-grade glioma (HGG) (WHO grade I

186 ly proven glioma (World Health Organization [WHO] grade II-IV) were examined with quantitative blood

187 cerebral gliomas (World Health Organization [WHO] grade II: 10 [including 1 patient with 2 lesions],

188 care, with stratification by tumour origin, WHO performance status, and previous somatostatin analog

189 attack, deaths, and casualties) to partners, WHO, United Nations Office for the Coordination of Human

190 Following these principles, WHO recommended that designated monitors in each of the

191 f the multidrug therapy components, prompted WHO in 1991 to set a global target of less than one case

192 al sites in South Africa, who were receiving WHO-recommended ART regimens and viral load monitoring.

193 Recent WHO guidelines recommend a boosted protease inhibitor pl

194 in these areas will require a reinvigorated WHO, with sustainable financing, greater multisector eng

195 ountries of the World Health Organization's (WHO's) South-East Asia Region (SEAR) in April 2016.The s

196 In 2013, the World Health Organization's (WHO's) Strategic Advisory Group of Experts (SAGE) recomm

197 eradicated, the World Health Organization's (WHO's) Strategic Advisory Group of Experts on Immunizati

198 e "switch." The World Health Organization's (WHO) Strategic Advisory Group of Experts (SAGE) on Immun

199 [-1.93 to 1.86]; p=0.97), disability score (WHO Disability Assessment Schedule score AMD 0.62 [-0.62

200 drinking, Short Inventory of Problems score, WHO Disability Assessment Schedule 2.0 score, days unabl

201 ts for application in low resource settings, WHO summarized their ideal features under the acronym AS

202 In the past two decades since WHO defined PPC and called for its inclusion in paediatr

203 Of the six WHO regions, the Eastern Mediterranean Region is project

204 that was interpreted using the standardized WHO methodology.

205 eces) and international reference standards (WHO/IUIS, two CBER/FDA), have been characterized.

206 eview of European Housing and Health Status (WHO-LARES) study on the effect of mold exposure on menta

207 NTERPRETATION: Our findings strongly support WHO's provisional strategy of biannual mass administrati

208 The WHO approach was effective in contacts younger than 5 ye

209 The WHO Child and Adolescent Mental Health Atlas, published

210 The WHO European Region had the highest prevalence (19.8 per

211 The WHO Framework Convention on Tobacco Control (WHO FCTC) h

212 The WHO global health sector strategy on viral hepatitis, cr

213 The WHO issued guidelines for DBAN after it was linked with

214 The WHO received confirmation that, by mid May 2016, all 155

215 with an average NO2 concentration above the WHO annual guideline in 2010 (3.0 times more likely in 2

216 ternate Mediterranean Diet Score (aMED), the WHO Healthy Diet Indicator (HDI), and the Baltic Sea Die

217 CI, 14.1-28.0 per 1000 population), and the WHO Eastern Mediterranean Region had the lowest (0.1 per

218 970 [9%] of 10 844 people; 8.4-9.5), and the WHO fasting glucose concentration cutoff (1213 [11%] of

219 rts, cancer control mission reports, and the WHO global NCD country capacity survey to identify the s

220 L), Web of Science, PubMed, Popline, and the WHO International Clinical Trials Registry Platform.

221 emia among adults and children on ART at the WHO-recommended threshold of >1,000 copies/ml on the Roc

222 ion and an exemplary partnership between the WHO, United Nations Children's Fund (UNICEF), and other

223 g lesions classified as grade I or II by the WHO classification of CNS tumors.

224 First, a survey designed by the WHO Department of Reproductive Health and Research was d

225 s were impaired functioning (measured by the WHO Disability Adjustment Schedule [WHODAS]), symptoms o

226 th Emergency of International Concern by the WHO in February of 2016.

227 eria, and Togo) collected and curated by the WHO Inter-country Support Team between 2005 and 2015.

228 As adequate surveillance as advocated by the WHO is limited, the Caribbean region could face an unide

229 susceptibility to treatment advocated by the WHO therapeutic guidelines.

230 rral test (TPP#2) have been published by the WHO.

231 ach and officially indexed as Cup s 2 by the WHO/IUIS allergen nomenclature.

232 coronary artery disease and calculating the WHO/International Society of Hypertension score.

233 creased to alarming levels, compromising the WHO-recommended first-line regimen.

234 ivalents per day of different countries, the WHO risk levels could also be used internationally to gu

235 Here, we describe the WHO-coordinated laboratory networks supporting VPD surve

236 iral treatment estimates to disaggregate the WHO paediatric tuberculosis incidence estimates by age,

237 d the Cochrane Library, MEDLINE, EMBASE, the WHO International Clinical Trials Registry Platform Sear

238 ly been proposed by the consensus group, the WHO, and the European Competence Network on Mastocytosis

239 ons, with 31 000 (36%, 19 000-59 000) in the WHO Africa region.

240 ion process is transparent as advised in the WHO ICD-11 revision agenda, we report the advances and u

241 bsection of ICD-11 and implementation in the WHO International Classification of Health Interventions

242 rs with and without symptoms included in the WHO pragmatic guideline (presence of haemoptysis, fever,

243 dren in ideal environments with those in the WHO reference sample.

244 ent in the JC virus sequences present in the WHO standard across multiple library preparations and se

245 strong implementation of the WHO FCTC in the WHO's Global Action Plan for the Prevention and Control

246 ections in tropical countries, including the WHO-defined neglected tropical diseases.

247 interventions with the aim of informing the WHO's global guidance on interventions to increase adher

248 rofiling Scoring Criterion (FSANZ-NPSC), the WHO Regional Office for Europe (EURO) model, the Pan Ame

249 Indeed, ODC is the target of the WHO "essential medicine" eflornithine, which is antagoni

250 A major revision of the WHO classification of lymphoid and myeloid neoplasms and

251 e been included in the current update of the WHO classification of myeloid neoplasms and AML, and mut

252 The 2016 revision of the WHO Classification of Tumours of Haematopoietic and Lymp

253 cco control demand-reduction measures of the WHO FCTC and smoking prevalence over the treaty's first

254 te the call for strong implementation of the WHO FCTC in the WHO's Global Action Plan for the Prevent

255 Despite the confirmed value of the WHO grading system, results of a multitude of studies an

256 Virological failure of the WHO-recommended first-line NNRTI-based regimen was highe

257 stewater CRE isolates (n = 1447) were on the WHO "critical pathogen" list in urgent need of new antib

258 d a three-tiered categorisation based on the WHO definition of unsafe abortion and WHO guidelines on

259 and verified with seroconversion panels, the WHO HBeAg standard, rHBeAg, and patient plasma samples.

260 This finding supports the WHO strategy for the eradication of yaws based on mass a

261 ralising titres equal to or greater than the WHO-specified protective antibody titre of 0.5 IU/mL.

262 ity of secondary standards calibrated to the WHO HEV international standard can improve the standardi

263 he amino acid distributions are close to the WHO recommendations, having e.g. 4.8% Lys, 2.7% Met+Cys,

264 d reached consensus statements to update the WHO position on causality.

265 nal databases worldwide increasingly use the WHO International Classification of Diseases (ICD) syste

266 head circumference were calculated using the WHO 2006 growth standards.

267 Using the WHO approach, 364 (21%) of 1718 child contacts had at le

268 were collected from clinical notes using the WHO Life Chart Schedule.

269 ar to that of previous evaluations using the WHO methodology for detecting consolidation, but poor fo

270 Using the WHO surgical safety checklist, a prominent example of a

271 Unlike tobacco, for which the WHO Framework Convention on Tobacco Control provides evi

272 a stepwise variance in concordance with the WHO healthy eating guidelines that aim to prevent non-co

273 ission efficiency (E) of the system with the WHO SP3-08 reference material.

274 tiated by the CDC, in collaboration with the WHO, to train and mobilize additional human resources to

275 Third, WHO convened a multidisciplinary panel of experts who as

276 uldering systemic mastocytosis, according to WHO classification or documented mastocytosis based on h

277 survival rates were calculated according to WHO criteria.

278 untries, but was most often low according to WHO indicators (<100 needle-syringes distributed per PWI

279 According to WHO recommendations, we classified BMI into categories o

280 sen discuss a cascade of HIV care adapted to WHO-recommended antiretroviral therapy irrespective of C

281 Nine of these subtypes are allotted to WHO grade I, and three each to grade II and grade III.

282 bran oils showed TPUFA/TSFA ratio closer to WHO recommended value.

283 tories submitted detailed monitoring data to WHO.

284 treat 83,000 L of contaminated water down to WHO limits which would be sufficient for 11,000 people.

285 This achievement, which owed much to WHO and the donors of the multidrug therapy components,

286 The new Director-General must transform WHO into a 21st century institution guided by the right

287 on by hospital site, site of primary tumour, WHO performance status, 16-week CT scan result, number o

288 s in the field, with emphasis on the updated WHO classification, refined criteria, additional prognos

289 We used WHO data from 126 countries to examine the association b

290 cobas 6800/8800 HCV and cobas 4800 HCV using WHO standard traceable panels representing HCV genotypes

291 retroviral therapy (ART) in programmes using WHO-recommended standardised regimens.

292 5 years, 65-74 years, and >/=75 years) using WHO Global Health Estimate (GHE) respiratory infection m

293 The primary endpoint was WHO-defined radiological pneumonia with pulmonary consol

294 The primary outcome was WHO Integrated Management of Childhood Illness (IMCI)-de

295 Outcomes were WHO-defined virological failure (one or more viral load

296 -NRTI-based first-line ART, as assessed with WHO criteria, confirmed by viral-load testing.

297 Response was assessed with WHO, RECIST, mRECIST, and EASL methods according to thei

298 core, analysed in an independent cohort with WHO grading, progression-free survival, and disease-spec

299 additional 13 countries were in contact with WHO for related congenital syphilis prevention activitie

300 children aged 1-59 months hospitalized with WHO-defined severe and very severe pneumonia from 7 low-